New schizophrenia pill enters human testing
NCT ID NCT07344948
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests an experimental oral drug called NTX-253 in healthy volunteers and people with stable schizophrenia. The main goal is to check safety and how the body processes the drug. 73 adults aged 18–55 will take single or multiple doses to find the right dose range and identify any side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Collaborative Neuroscience Research, LLC - CenExel
RECRUITINGLos Alamitos, California, 90720, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mind over movement: can imagining exercise boost balance and brainpower?
- Can a cancer drug be tailored for japanese patients? a new trial seeks answers
- Which pill works best? a trial puts elecoglipron formulations to the test
- Vitamin c may shield postmenopausal hearts without hormones
- Inhaled experimental drug targets tough lung infections
- Meal timing and stomach acid drugs may change how this experimental drug works